Clinical trials: Breast Cancer (Triple Negative Breast Cancer (TNBC))
Triple-Negative Breast Cancer (TNBC)
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring…
- Trial name
- NCT07005583
- Testing
- QL1706 Plus Olaparib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
TNBC
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
The goal of this study is to explore the efficacy and safety of sacituzumab govitecan in combination with toripalimab as first - line treatment in patients with advanced triple - negative breast cancer.
- Trial name
- NCT06991790
- Testing
- Sacituzumab Govitecan (SG)+Toripalimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking University Cancer Hospital & Institute
Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)
- Conditions
- Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects
- Trial name
- NCT06975644
- Testing
- nab-paclitaxel, carboplatin, and bemotuzumab, epirubicin, cyclophosphamide, and bemotuzumab
- Volunteers
- 55 people
- Sponsor
- Zhejiang Provincial People's Hospital
Triple Negative Breast Cancer (TNBC)
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC.
- Trial name
- NCT03742349
- Testing
- spartalizumab, LAG525, NIR178
- Where
- 13 sites in United States, Australia and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment.
- Trial name
- OPTImaL (NCT06476119)
- Testing
- Adjuvant chemotherapy, No adjuvant chemotherapy
- Where
- 28 sites in Netherlands
- Volunteers
- 490 people
- Sponsor
- The Netherlands Cancer Institute
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Triple Negative Breast Cancer (TNBC)
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who…
- Trial name
- NCT05555706
- Testing
- B013+Nab-Paclitaxel
- Where
- 13 sites in China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Triple Negative Breast Cancer (TNBC)
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
- Trial name
- CIRCADIAN (NCT06880029)
- Testing
- Morning pembrolizumab infusions
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Triple Negative Breast Cancer (TNBC)
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of…
- Trial name
- TNBC (NCT03554109)
- Testing
- Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
TNBC, Triple Negative Breast Cancer
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
- Trial name
- NCT06786026
- Testing
- bevacizumab, QL1706, Nab paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
The aim of this trial is to explore the real-world patient-reported health-related quality of life (HRQOL), functioning, symptoms and symptom tolerability of sacituzumab govitecan or chemotherapy of the physician's choice for…
- Trial name
- NCT06798506
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Triple-Negative Breast Cancer (TNBC), Brain Metastases
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab…
- Trial name
- BALISTA (NCT06793332)
- Testing
- Ivonescimab Combined With TROP2 ADC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer
Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients
The goal of this trial is to learn if a home-based exercise program (intervention) reduces fatigue and improves quality of life in adult patients with early breast cancer who are proposed for preoperative chemotherapy.
- Conditions
- Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer, Early Breast Cancer, Cancer-related Fatigue
- Trial name
- HoPEx-Breast (NCT06782698)
- Testing
- Home-based exercise program, Promotion of Healthy Physical Activity
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalar Universitário de Santo António
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer (TNBC)
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
All trans retinoic acid Combined with Toripalimab+Chemotherapy for Locally Advanced inoperable or Metastatic Triple Negative Breast Cancer：a multi-center, multi-cohort phase II trial
- Trial name
- NCT06636981
- Testing
- Cohort2: ATRA+Toripalimab+TPC, Cohort1: ATRA+Toripalimab+chemo
- Where
- 2 sites in China
- Volunteers
- 129 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
This is a prospective, open-label, randomized phase II clinical study which recruits unresectable recurrent or metastatic triple-negative breast cancer resistant to immunotherapy.
- Trial name
- NCT06731153
- Testing
- Ivarmacitinib, Camrelizumab (SHR-1210), Eribulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer (TNBC)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally recurrent inoperable or metastatic…
- Trial name
- NCT02819518
- Testing
- Pembrolizumab, Nab-paclitaxel, Paclitaxel
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC